Shots:

• UCB will acquire all outstanding shares of Zogenix for $26.00/share in cash & milestone-based CVR of $2.00/share upon achievement of EU approval of Fintepla for LGS by Dec 31, 2023 making a total value of $1.9B representing a premium of 72% to avg. closing stock price of Zogenix. The transaction is expected to close at the end of Q2’22
• The acquisition will expands & builds upon UCB's role & adds Fintepla to UCB's existing product line to addres unmet needs of people living with specific or rare forms of epilepsy
• Fintepla has been approved in the US & EU and is under regulatory review in Japan for the treatment of seizures associated with Dravet syndrome in patients aged ≥2yrs.

Ref: Zogenix | Image: Trading View